GEMCITABINE IN NONSMALL CELL LUNG-CANCER

被引：5

作者：

SORENSEN, JB

机构：

[1] Department of Oncology, National University Hospital/Rigshospitalet, DK-2100 Copenhagen

来源：

LUNG CANCER | 1995年 / 12卷

关键词：

NONSMALL CELL LUNG CANCER; PHASE II TRIAL; CHEMOTHERAPY; ANTIMETABOLITE; GEMCITABINE; SINGLE AGENT TREATMENT;

D O I：

10.1016/0169-5002(95)00433-2

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The pyrimidine antimetabolite gemcitabine is an analogue of cytosine arabinosid. Gemcitabine is well tolerated when given in doses of 1000-1250 mg/m(2) weekly x 3 followed by 1 weeks rest, with mild myelosuppression as the major toxicity. In five studies, including a total of 250 patients with previously untreated non-small cell lung cancer (NSCLC), response rates from 20 to 28% were observed, ranking gemcitabine among the active agents in NSCLC. Gemcitabine should be further explored in combination therapy for NSCLC.

引用

页码：S173 / S175

页数：3